2022-10 – European Patent office has Published a SER150 patent 19th October 2022

Serodus ASA, Heia 8, N-0268 Oslo, Norway, Org. No. 992 249 897 www.serodus.com Serodus ASA Announces that European Patent office has Published a SER150 patent 19th October 2022 Company Announcement October 24, 2022 SER150 significantly reduced the albumin content in urine in patients suffering from type 2 diabetes who had albumin (protein) in urine as a clinical sign of diabetes induced renal disease 25% of the patients had no albumin in urine after only 4 weeks treatment with SER150. 45% of the diabetic patients who had very high amount of albumin when SER150 treatment was initiated the albumin was reduce to micro-albuminuria levels. Oslo, Norway October 24, 2022 - Serodus is a biotech company focused on developing our lead compound SER150 for the treatment of diabetic kidney disease, a complication seen in many patients suffering from type 2 diabetes. It is well known that a well-controlled blood glucose concentration and treatment with specific antihypertensive compounds delay the time to dialysis which is the treatment of end-stage renal disease. Inflammation in addition to high blood glucose concentration and blood pressure in the renal organ are all of importance for the development of the diabetic renal complication. SER150 is a thromboxane receptor antagonist and a synthase inhibitor. Thromboxane is a substance primarily liberated from thrombocytes and involved in coagulation, but it has also pro-inflammatory properties. Patients with diabetes has an increased thromboxane production and by treatment with SER150 Serodus expect to reduce loss of kidney function in diabetic patients. SER150 is expected to demonstrate additive effect to lowering blood glucose concentration and combined treatment specific antihypertensive compounds. “We are extremely pleased with the announcement of the new patent which has a priority date in 2020. We are also happy to inform that our next clinical study is performed in Australia and just about to open centers in New Zealand” said Eva Steiness, M.D.,CEO of Serodus. Contacts: Eva Steiness, M.D. CEO Serodus Email: [email protected] Serodus ASA, Heia 8, N-0268 Oslo, Norway, Org. No. 992 249 897 www.serodus.com Serodus ASA Announces that European Patent office has Published a SER150 patent 19th October 2022 Company Announcement October 24, 2022 SER150 significantly reduced the albumin content in urine in patients suffering from type 2 diabetes who had albumin (protein) in urine as a clinical sign of diabetes induced renal disease 25% of the patients had no albumin in urine after only 4 weeks treatment with SER150. 45% of the diabetic patients who had very high amount of albumin when SER150 treatment was initiated the albumin was reduce to micro-albuminuria levels. Oslo, Norway October 24, 2022 - Serodus is a biotech company focused on developing our lead compound SER150 for the treatment of diabetic kidney disease, a complication seen in many patients suffering from type 2 diabetes. It is well known that a well-controlled blood glucose concentration and treatment with specific antihypertensive compounds delay the time to dialysis which is the treatment of end-stage renal disease. Inflammation in addition to high blood glucose concentration and blood pressure in the renal organ are all of importance for the development of the diabetic renal complication. SER150 is a thromboxane receptor antagonist and a synthase inhibitor. Thromboxane is a substance primarily liberated from thrombocytes and involved in coagulation, but it has also pro-inflammatory properties. Patients with diabetes has an increased thromboxane production and by treatment with SER150 Serodus expect to reduce loss of kidney function in diabetic patients. SER150 is expected to demonstrate additive effect to lowering blood glucose concentration and combined treatment specific antihypertensive compounds. “We are extremely pleased with the announcement of the new patent which has a priority date in 2020. We are also happy to inform that our next clinical study is performed in Australia and just about to open centers in New Zealand” said Eva Steiness, M.D.,CEO of Serodus. Contacts: Eva Steiness, M.D. CEO Serodus Email: [email protected]

The release as fetched from its publisher. serodus.com ↗